Novartis Reports final analysis Data for Treprostinil in Hemophilia A

Novartis today announced final analysis results for Treprostinil in patients with Hemophilia A. The study demonstrated that Treprostinil reduces disease progression risk by over 40% compared to standard of care or placebo. These results provide important insights into the treatment of Hemophilia A and support the continued development of Treprostinil in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Treprostinil was consistent with previous observations, with no new safety signals identified.